HumacyteHUMA
HUMA
About: Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
Employees: 185
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
112% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 25
100% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 18
29% more capital invested
Capital invested by funds: $151M [Q2] → $194M (+$43.7M) [Q3]
15% more funds holding
Funds holding: 123 [Q2] → 141 (+18) [Q3]
3.57% more ownership
Funds ownership: 26.37% [Q2] → 29.94% (+3.57%) [Q3]
54% less call options, than puts
Call options by funds: $1.52M | Put options by funds: $3.3M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
116%
upside
Avg. target
$16.67
259%
upside
High target
$25
439%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 25% 1-year accuracy 38 / 150 met price target | 439%upside $25 | Buy Maintained | 20 Dec 2024 |
HC Wainwright & Co. Vernon Bernardino 32% 1-year accuracy 19 / 59 met price target | 223%upside $15 | Buy Reiterated | 20 Dec 2024 |
EF Hutton Jason Kolbert 25% 1-year accuracy 38 / 150 met price target | 439%upside $25 | Buy Maintained | 28 Oct 2024 |
TD Cowen Joshua Jennings 42% 1-year accuracy 8 / 19 met price target | 116%upside $10 | Buy Reiterated | 18 Oct 2024 |
BTIG Ryan Zimmerman 63% 1-year accuracy 30 / 48 met price target | 116%upside $10 | Buy Reiterated | 18 Oct 2024 |
Financial journalist opinion
Based on 330 articles about HUMA published over the past 30 days
Neutral
Accesswire
4 hours ago
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their Options NEW YORK, NY / ACCESSWIRE / December 21, 2024 / If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ:HUMA) and reminds investors of the January 17, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Neutral
GlobeNewsWire
13 hours ago
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”), of the important January 17, 2025 lead plaintiff deadline.
Neutral
Accesswire
23 hours ago
Shareholders of Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights - HUMA
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=117834&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
23 hours ago
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Humacyte, Inc. (HUMA)
LOS ANGELES, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 17, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities between May 10, 2024 and October 17, 2024, inclusive (the “Class Period”).
Neutral
Invezz
1 day ago
Humacyte stock may fail to sustain today's gains: find out more
Shares of Humacyte Inc (NASDAQ: HUMA) nearly doubled on Friday after receiving full approval for its flagship SYMVESS product from the US Food and Drug Administration (FDA). Regulatory approval for the company's bioengineered human tissue marks a major step forward in regenerative medicine and trauma care.
Neutral
Accesswire
1 day ago
Humacyte, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights - HUMA
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=117809&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
1 day ago
The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Case Against Humacyte Inc.
LOS ANGELES, CA / ACCESSWIRE / December 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 10, 2024, and October 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 17, 2025.
Neutral
Accesswire
1 day ago
Humacyte, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights - HUMA
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=117799&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
1 day ago
Humacyte's (HUMA) Insiders Sell Millions in Stock Amidst Lawsuit and Regulatory Troubles - Hagens Berman
SAN FRANCISCO, CA / ACCESSWIRE / December 20, 2024 / Humacyte insiders recently offloaded a significant portion of company stock, raising eyebrows amidst a brewing legal storm. According to recent SEC filings, Ayabudge LLC, an entity controlled by Board member Brady W.
Positive
Benzinga
1 day ago
Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday?
On Thursday, the FDA granted full approval to Humacyte, Inc.'s HUMA Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and when autologous vein graft is not feasible.
Charts implemented using Lightweight Charts™